The invention is related to the preparation of bivalent compounds comprises a tropomyosin receptor kinase (TRK) ligand conjugated to a degradation tag, e.g., I, or a pharmaceutically acceptable salt or analog thereof, wherein the TRK ligand is capable of binding to a TRK protein comprising TRK, a TRK mutant, TRK deletion, or a TRK fusion protein or the TRK ligand is a TRK kinase inhibitor or a portion of TRK kinase inhibitor and the degradation tag binds to an ubiquitin ligase, e.g., an E3 ligase, or is a hydrophobic group or a tag that leads to misfolding of the TRK protein. Thus, reacting (R)-6-[2-(3-fluorophenyl)pyrrolidin-1-yl]-3-[6-(piperazin-1-yl)pyridin-2-yl]imidazo[1,2-b]pyridazine (preparation given) with [2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl]glycine (preparation given) gave I. I reduced the overexpressed TPM3-TRKA, AGBL4-TRKB and ETV6-TRKC fusion protein levels, and of TRKA protein levels in a concentration-dependent manner. The degradation of I was dependent on the ubiquitin-proteasome system, because it was neutralized by co-administration of proteasome inhibitors, MG-132 and bortezomib, a cullin E3 ligase inhibitor, MLN4924, or high concentration of pomalidomide that compete for cereblon binding. A method for identifying a bivalent compound which mediates degradation or reduction of TRK by providing a heterobifunctional test compound comprising a TRK ligand conjugated to a degradation tag through a linker; contacting the heterobifunctional test compound with a cell comprising a ubiquitin ligase and TRK; determining whether TRK level is decreased in the cell; and identifying the heterobifunctional test compound as a bivalent compound which mediates degradation or reduction of TRK wherein the cancer cell is a TRK-mediated cancer cell is also described.